ROVI is pivoting from pandemic-era CDMO volatility to durable U.S./EU biologics manufacturing and proprietary long-acting injectables—while racing to de-risk a heparin supply chain tied to China.
Overview
Laboratorios Farmaceuticos Rovi, S.A. is a Madrid-based, fully integrated specialty pharma company and a globally relevant sterile-injectables CDMO. The business is intentionally “two-engine”: (1) a cash-generative Specialty Pharmaceutical segment anchored by low-molecular-weight heparins—Bemiparin (Hibor) and an Enoxaparin biosimilar—sold via a direct Spanish commercial footprint and an out-licensing network spanning 80+ territories; and (2) a high-growth CDMO segment focused on aseptic fill-and-finish (pre-filled syringes, vials, cartridges) across FDA/EMA-approved facilities. The specialty portfolio is increasingly defined by proprietary long-acting injectables in psychiatry/neurology, led by Okedi (Risperidone ISM; Risvan in the U.S.), plus a set of marketed/licensed hospital and specialty products (contrast agents, Neparvis, Volutsa, Orvatez). The CDMO arm gained global prominence through Moderna’s mRNA COVID-19 vaccine manufacturing work and is now transitioning from pandemic-linked volumes toward durable biologics and oncology manufacturing contracts. Revenue is diversified across product sales, royalties/milestones from out-licensing, and long-term manufacturing fees—helping reduce single-payer concentration. Strategically, stable heparin cash flows fund both CDMO capacity expansion and long-duration clinical development for the ISM platform, creating a defensible moat in complex injectable manufacturing and delivery technology.